Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its lead drug candidate, Lucid-MS, into a Phase 2 clinical trial in patients with multiple sclerosis, according to comments made by co-founder and executive co-chair Anthony Durkacz on The BioMedWire Podcast. The trial will mark the first time the drug is tested in MS patients, Durkacz said. Lucid-MS targets myelin and has been shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis.
The move into Phase 2 testing is a critical milestone for the company and for patients, as it represents the first clinical evaluation of Lucid-MS in the target patient population. If successful, the trial could pave the way for a new treatment approach for MS, a chronic disease with limited options for restoring myelin. For investors, the advancement signals progress in Quantum’s pipeline and potential long-term value creation. The company is focused on building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders and alcohol misuse disorders through its wholly owned subsidiary, Lucid Psycheceuticals Inc. More details are available in the company’s newsroom at Quantum BioPharma Ltd..
Durkacz also discussed the commercial opportunity surrounding unbuzzd™, a product designed to accelerate alcohol metabolism. Quantum invented unbuzzd™ and spun out its over-the-counter version to Unbuzzd Wellness Inc., which is led by industry veterans. Quantum retains a 19.84% ownership stake in Unbuzzd as of March 31, 2026, and holds a 7% royalty on sales until payments to Quantum total $250 million. After that threshold, the royalty drops to 3% in perpetuity. Quantum also retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses, which could open additional revenue streams. The full press release is available at https://ibn.fm/ovRTM.
The interview was conducted by BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For investors, the podcast and associated press release offer insight into Quantum’s dual strategy: advancing a novel MS therapy while monetizing an already commercialized consumer health product. The company’s ability to execute on both fronts could influence its valuation and attractiveness to partners. The latest updates on QNTM are available in the company’s newsroom at Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM).
As with any clinical-stage biopharmaceutical company, risks remain, including the inherent uncertainty of drug development and regulatory outcomes. However, the upcoming Phase 2 trial and the royalty stream from unbuzzd™ provide two distinct catalysts that investors and industry observers will be watching closely. The full terms of use and disclaimers for BioMedWire content can be found at https://www.BioMedWire.com/Disclaimer.
